Log in to your Inderes Free account to see all free content on this page.
Zelluna
Less than 1K followers
ZLNA
Oslo Børs
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.
Read moreMarket cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
12.2.
2026
Annual report '25
23.4.
2026
General meeting '26
7.5.
2026
Interim report Q1'26
All
Press releases
3rd party
ShowingAll content types
ZLNA: Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio